Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study

摘要

Chronic hepatitis C virus (HCV) genotype (GT) 3 infection with advanced liver disease has emerged as a challenging to treat by direct-acting antivirals (DAAs), but the efficacy of DAAs in Chinese HCV-GT3 patients is rarely reported. This study aimed to analyze the efficacy of sofosbuvir (SOF)-based regimens in Chinese patients with HCV-GT3 and compensated liver disease. This was a registered retrospective study. All patients had completed at least 12?weeks SOF-based regimens therapy (with or without RBV), and were followed up for at least 24?weeks after therapy discontinuation. The primary endpoint was sustained virological response 24?weeks after end of therapy (SVR24). A total of 102 patients who completed at least 12?weeks therapy were finally included, with 57 in SOF?+?Daclatasvir (SOF?+?DCV), 24 in SOF?+?DCV?+?ribavirin (RBV) and 21 in SOF/Velpatasvir (SOF/VEL). The total SVR24 rate was achieved in 90.20% (92/102), with 85.96% (49/57) in SOF?+?DCV, 91.67% (22/24) in SOF?+?DCV?+?RBV and 100.00% (21/21) in SOF/VEL. Among 10 relapsed patients (8 in SOF?+?DCV and 2 in SOF?+?DCV?+?RBV), the short course (12?weeks) of therapy and no RBV addition may be the leading cause. In this cohort, the SVR24 rate was not statistically different between patients with and without cirrhosis (81.82% [27/33] vs. 94.20% [65/69], P?=?0.073). Additionally, both FIB-4 (4.03 vs. 2.08, P??0.001) and APRI (2.15 vs. 0.68, P??0.001) scores were significant improved from baseline to week 24 after completion of therapy, regardless of the presence of cirrhosis. SOF-based regimens are highly effective in viral clearance and fibrosis remission for Chinese patients with HCV-GT3 infection. If available, SOF/VEL should be first considered.